Journal
VACCINE
Volume 23, Issue 15, Pages 1828-1832Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2004.11.013
Keywords
algae; Chlamydomonas reinhardtii; IgA; human monoclonal antibodies; single chain antibodies
Categories
Funding
- NIAID NIH HHS [R01 AI059614-02, R01 AI059614] Funding Source: Medline
- NIGMS NIH HHS [R01GM54659] Funding Source: Medline
Ask authors/readers for more resources
Protein based therapeutics have enjoyed great success over the past decade. Unfortunately, with this clinical success comes a heavy price tag, owing to the inherently high costs of capitalization and production using mammalian cell fermentation. To address this problem, we have begun developing a system for the expression of recombinant proteins in the unicellular eukaryotic green algae, Chlamydomonas reinhardtii, leading to the production of human IgA single chain antibodies. The expression of human monoclonal antibodies in C. reinhardtii offers an attractive alternative to traditional mammalian based expression systems for several reasons, including an ability to rapidly obtain stable plastid and nuclear transformants, coupled with inherently low costs of capitalization and production. (c) 2004 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available